^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR V774_C775insHV

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4years
    [VIRTUAL] Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma (IASLC-WCLC 2020)
    Targeted therapy was followed, including afatinib and osimertinib...The first-line treatment was pemetrexed, nedaplatin plus bevacizumab and the second-line treatment was docetaxel plus carboplatin...Patient 4, a 57-year-old female, stage IVB with EGFR 20 ins (D770del) , she received first-line pemetrexed and carboplatin plus pembrolizumab...After the progression of first-line treatment of osimertinib, he received nab-paclitaxel, carboplatin, bevacizumab and durvalumab...It is not clear whether this regimen is appropriate for each of the 20 insertion sites. The therapeutic combination will need more real-world evidences.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR V774_C775insHV
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tagrisso (osimertinib) • Gilotrif (afatinib) • carboplatin • Imfinzi (durvalumab) • docetaxel • albumin-bound paclitaxel • pemetrexed • Aqupla (nedaplatin)